Contract for Supply of Herpes Zoster (Shingles) Vaccine (Recombinant, Adjuvanted)

Concepts

• vaccines
• supply of herpes zoster
• provision of herpes zoster
• shingles
• vaccine
• recombinant
• adjuvanted
• april
• march

Location

Bedford, UK

Description

The provision of herpes zoster (shingles) vaccine (recombinant, adjuvanted).

Total Quantity or Scope

The provision of herpes zoster (shingles) vaccine (recombinant, adjuvanted) deliveries will be required from 1 April 2021 to 31 March 2023, with an option to extend for up to an additional 24 months.

Award Detail

Renewal Options

The contract has the option to be extended for up to an additional 24 months.

Award Criteria

CPV Codes

• 33651600 - Vaccines

Indicators

• Options are available.
• Award on basis of price and quality.

Legal Justification

There is only one supplier with an exclusive global licence to manufacture and distribute this vaccine which is licensed and approved for use in the UK and due to the functions of the vaccine, there is no reasonable alternative or substitute, therefore using the negotiated procedure without prior publication is justified under Regulation 32(2)(b)(ii) and (iii) of the Public Contracts Regulations 2015.

Other Information

This notice has previously been published in ‘Find a Tender Service’ (FTS), the UK e-Notification service. Publication in the Official Journal of the European Union was delayed by a technical issue on behalf of the EU publications Office, which has now been resolved. The contract(s) is for the benefit of the contracting authority and NHS bodies along with any other non-NHS bodies which are necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments and their executive agencies or non-departmental public bodies charged with the delivery of healthcare or health related services in the United Kingdom, Crown Dependencies and British Overseas Territories including, without limitation, the National Assembly for Wales, the Northern Ireland Assembly, and Scottish Ministers. The resulting products delivered against the contract(s) may be made available to the UK devolved administrations, Crown Dependencies and British Overseas Territories to undertake their respective vaccination programmes.